Latest news with #JeffreySpector
Business Insider
19 hours ago
- Business
- Business Insider
Sabra Healthcare REIT (SBRA) Receives a Buy from Bank of America Securities
In a report released on July 8, Jeffrey Spector from Bank of America Securities reiterated a Buy rating on Sabra Healthcare REIT, with a price target of $20.00. The company's shares closed yesterday at $18.46. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Spector covers the Real Estate sector, focusing on stocks such as Agree Realty, Cousins Properties, and Welltower. According to TipRanks, Spector has an average return of 3.2% and a 46.63% success rate on recommended stocks. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Sabra Healthcare REIT with a $19.67 average price target. The company has a one-year high of $20.03 and a one-year low of $15.60. Currently, Sabra Healthcare REIT has an average volume of 2.55M. Based on the recent corporate insider activity of 68 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of SBRA in relation to earlier this year. Most recently, in May 2025, Michael J Foster, a Director at SBRA sold 11,000.00 shares for a total of $200,310.00.
Business Insider
19 hours ago
- Business
- Business Insider
Bank of America Securities Sticks to Its Buy Rating for CareTrust REIT (CTRE)
Bank of America Securities analyst Jeffrey Spector reiterated a Buy rating on CareTrust REIT on July 8 and set a price target of $32.00. The company's shares closed yesterday at $30.73. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. According to TipRanks, Spector is a 3-star analyst with an average return of 3.2% and a 46.63% success rate. Spector covers the Real Estate sector, focusing on stocks such as Agree Realty, Cousins Properties, and Welltower. Currently, the analyst consensus on CareTrust REIT is a Moderate Buy with an average price target of $31.83. The company has a one-year high of $33.15 and a one-year low of $24.79. Currently, CareTrust REIT has an average volume of 1.68M.
Yahoo
06-05-2025
- Business
- Yahoo
Lineage Stock Forecast Slashed By 30%
BofA Securities analyst Jeffrey Spector downgraded Lineage Inc (NASDAQ:LINE) to Neutral from Buy on Tuesday and lowered the price forecast from $70.00 to $49.00. The analyst downgraded LINE and lowered the price target, citing reduced visibility driven by persistent revenue growth challenges, halted supply chain investments, and downward earnings revisions. Spector noted that producers are delaying key decisions on expansions, plant locations, and transportation sourcing due to macroeconomic uncertainty driven by tariffs. Lineage reported first-quarter 2025 EPS of $0.01, exceeding analyst expectations of a $ 0.05 loss, and posted revenue of $1.29 billion, which fell short of the $1.34 billion consensus estimate. The Company maintains its full-year 2025 outlook, projecting adjusted EBITDA between $1.35 billion and $1.40 billion, and adjusted FFO per share in the range of $3.40 to $3.60. The analyst stated that Lineage reported Q1 AFFO of $0.86, surpassing both their $0.80 estimate and the $0.85 consensus. However, revenue declined 4.2% compared to their projected 2.1% growth, driven by lower occupancy, reduced throughput volumes, and softer pricing in both storage and services. Spector added that the 2025 AFFO guidance was upheld, partly due to recent acquisitions, including the Tyson Foods (NYSE:TSN) deal. The analyst lowered the 2025 occupancy growth forecast to -1.7% from -0.6% and reduced 2025 throughput volume growth to -1.6% from +1.5%. 2026 occupancy growth remains flat, with throughput growth revised down to +0.3% from +1.5%. The analyst revised 2025 occupancy growth down to -1.7% from -0.6%, and reduced throughput volume growth to -1.6% from +1.5%. For 2026, occupancy growth is expected to remain flat, while throughput growth is now forecasted at +0.3%, down from +1.5%. Here are other recent analyst ratings on Lineage and their price targets: Piper Sandler: Maintained an Overweight rating, lowered price target from $75 to $60 Baird: Maintained Outperform rating, lowered price target from $70 to $64 Evercore ISI Group: Maintained an Inline rating, lowered price target from $68 to $59 UBS: Maintained Neutral rating, lowered price target from $62 to $49 Price Action: LINE shares closed lower by 1.13% to $43.78 on Tuesday. Read Next: Photo via Shutterstock Latest Ratings for LINE Date Firm Action From To Mar 2016 Goldman Sachs Terminates Coverage On Sell Feb 2016 Wells Fargo Downgrades Market Perform Underperform Feb 2016 Citigroup Downgrades Neutral Sell View More Analyst Ratings for LINE
